Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

ResQ Pharma receives PDUFA date for LipidRescue™, potentially the first FDA-approved treatment for Local Anesthetic Systemic Toxicity (LAST)

frequent speaker and guest lecturer around the world. The privately-held company is based in Chicago, Illinois. For more information please visit www.ResQPharma.com.

Bracco Diagnostics Inc. reaches one million injections milestone with its MRI agent, VUEWAY® (gadopiclenol)

organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. For more information please visit, www.bracco.com

SystImmune secures FDA clearance for BL-M17D1 IND in advanced solid tumors

Chief Executive Officer of SystImmune, commented, "Our mission at SystImmune is to bring therapies that can provide transformative clinical benefit to patients. As BL-M17D1 is developed using our next generation linker and payload technology, the...

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced that results from its Phase...

Aadi Bioscience reports Q3 2024 financial results and updates on corporate progress

with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). For more information please visit, www.aadibio.com

Cure51 selects 10x Genomics Visium HD to drive its new drug discovery initiative

proprietary multi-omics database of exceptional cancer survivors. 10x Genomics' Visium HD assay, enables researchers to perform whole transcriptome spatial gene expression analysis at single cell-scale resolution. The assay will enable Cure51's...

GoodRx debuts a new e-commerce platform, starting with Opill®

GoodRx the leading prescription savings platform in the U.S., announced the rollout of its new e-commerce solution, with Opill® as its launch partner. This new seamless direct-to-consumer shopping experience allows consumers to order eligible...

Vensica Medical raises $11M to advance Phase 2 trials for its overactive bladder treatment

to offer patients a less invasive, more comfortable treatment option compared to traditional injections, potentially transforming the standard of care for OAB. Vensica's needle-free drug delivery system aims to be a urology treatment platform for...

GC Biopharma and Novelty Nobility sign an R&D agreement to develop therapies for geographic atrophy

elderly, is divided into two types: dry and wet. Often occurring in the late stages of AMD progression, GA is an advanced form of dry AMD that causes damage to retinal tissue, eventually leading to blindness. In the US alone, approximately 1.5...

BioCryst shares real-world data highlighting strong adherence and persistence with ORLADEYO® (berotralstat)

once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com

2nd International Conference on Biotechnology and Bioengineering 2024

talents, and research in the realm of biotechnology. The Biotechnology Congress 2024 provides an exceptional platform for researchers, exhibitors, investigators, doctors, professors, scholars, delegates, and students to come together to explore,...

3rd BioPharma 2024

Get ready to connect, learn, and exchange ideas as we explore the cutting-edge strategies that optimize site performance and drive successful clinical trial.

Great Bay Bio launches its Intelligent Drug Development Ecosystem

future, Great Bay Bio will adhere to technological innovation and work with global partners to further promote the transformation and development of the biopharmaceutical industry, so that patients around the world can enjoy the benefits brought by...

ARTHEx Biotech doses first patient in Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1

outcomes, and quality of life measures. The plan is to enroll fifty-six participants to allow an assessment of ATX-01's performance in this population. Dr. Judy Walker, Chief Medical Officer of ARTHEx, added, "The ArthemiR™ trial is designed to...

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults. For more information please visit, www.claritypharmaceuticals.com

Aileron Therapeutics will present Phase 1b trial data on low-dose LTI-03 for IPF at the 22nd International Colloquium on Lung and Airway Fibrosis

further supports the potential therapeutic effectiveness of LTI-03 for IPF through precision cut lung slices (PCLS) performed ex-vivo. Pre-clinical studies demonstrated molecular activity in IPF PCLS explants indicative of fibrosis during five days...

Blue Earth Therapeutics shares positive Phase 1 results for Lutetium (177Lu) rhPSMA-10.1 Injection, advancing its clinical development

Injection was completed in July. Early data from the trial suggests an encouraging safety profile. Radiation dosimetry performed for up to three cycles showed delivery of high tumour absorbed radiation doses relative to the dose delivered to the...

Prendio-BioProcure presents PrendioPay, simplifying procurement for life science companie

leader in procurement solutions for the life science industry, is excited to launch PrendioPay, an integrated payment platform that evolves the operational reality that most biotech companies face in their business today – separate systems,...

Disruptive Technology for Clinical Trials Summit 2024

streamline processes, and drive innovation in clinical research. From AI integration to decentralized trial platforms, innovative solutions are reshaping the way trials are designed, conducted, and analyzed for efficiency. Yet, alongside this...

HNSA-5487 reduced IgG by over 95% in a first-in-human trial, showing redosing potential

profile compared to published data from studies with other IgG-targeted therapies. These results underscore the transformational potential of HNSA-5487 to address significant unmet need across a spectrum of IgG driven diseases and conditions,...